Meeting
2011 ASCO Annual Meeting
Phase II trial of sunitinib in renal cell cancer with untreated brain metastases.
Authors
C. Chevreau
Institut Claudius Regaud, Toulouse, France
C. Chevreau , A. Ravaud , B. Escudier , A. Caty , R. Delva , F. Rolland , S. Oudard , R. Herve , E. Blanc , C. Ferlay , N. Lignon , S. Negrier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT00814021
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4625)
Abstract #
4625
Poster Bd #
8A
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analysis of SURF study.
First Author: Antoine Thiery-Vuillemin
Poster
2018 ASCO Annual Meeting
CABOPRE: Phase II study of cabozantinib prior to cytoreductive nephrectomy (CN) in locally advanced and/or metastatic renal cell carcinoma (mRCC).
First Author: Guillermo de Velasco
Poster
2017 ASCO Annual Meeting
Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carinoma.
First Author: Eric Jonasch
Poster
2017 Genitourinary Cancers Symposium
A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma.
First Author: Eric Jonasch